NIKKEI 225
38,356.06 +176.60 (+0.46%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.41 +0.39 (+0.50%) GOLD FUTURES
2,361.90 +2.00 (+0.08%) DOW
39,558.11 +126.60 (+0.32%) Bitcoin GBP
49,013.09 -874.85 (-1.75%)
NVO Jul 2024 195.000 call
| Previous close | 0.1400 |
| Open | 0.1600 |
| Bid | 0.0300 |
| Ask | 0.1400 |
| Strike | 195.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1400 - 0.1600 |
| Contract range | N/A |
| Volume | |
| Open interest | 71 |
- Reuters
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday. As part of the deal, Totality Medispa will make a monetary payment to Lilly and will no longer use Lilly branding in the promotion of any of its products. The medi spa is expected to take several corrective actions including obtaining and distributing compounded tirzepatide products that are produced in compliance with U.S. federal law.
BloombergOzempic Maker Novo Sells $5 Billion in Bonds to Fund Deal
(Bloomberg) -- Novo Nordisk A/S is selling €4.65 billion ($5 billion) in bonds to fund plans to ramp up production of its blockbuster drugs, drawing high investor demand for its first debt issuance in more than two years.Most Read from BloombergTrump Vows ‘Day One’ Executive Order Targeting Offshore WindBiden Accuses China of ‘Cheating’ on Trade, Imposes New TariffsFlood of China Used Cooking Oil Spurs Call to Hike US LeviesMacron Puts French Banks in Play With Plan to Transform EuropeHow One of
ZacksNovo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
